Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR(TM) in Discussions with Leading Cutaneous Lymphoma Experts

Stock Information for Citius Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Pharmaceuticals Inc.

Citius Oncology Provides Commercial Update on LYMPHIR(TM) Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR(TM) (E7777) Dosing Prior to Commercial CAR?T Therapy in High?Risk Diffuse Large B?Cell Lymphoma
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM)
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM)
Citius Oncology Expands International Distribution of LYMPHIR(TM) to European Union Through Exclusive Agreement with Uniphar
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.